With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.

In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients, the 4^th Rare & Genetic Kidney Disease Drug Development Summit returned to Boston. This unique event for the industry, academic KOL, and patient advocacy nephrology community provided an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations.

2024's meeting brought together 30+ expert speakers, a two-tracked pre-conference workshop day and new content on podocyte biology, tissue bioengineering of kidney tissue models, market access strategies, as well as pricing and reimbursement conversations, across a breadth of rare renal therapeutic areas including FSGS, PKD, Alport Syndrome and IgAN to name but a few!